Abstract
Introduction
C
The Clinical Scenario
The patient had recurrent episodes of urticaria and angioedema. Therefore, she was treated with corticosteroids and antihistamines. The dose of H1-antihistamines was increased up to 4 times the standard dosage. This dose caused a partial improvement of symptoms. However, when the treatment was interrupted, a relapse appeared within days after cessation of treatment. Similarly to other cases of CU, in this case the etiology of hives was not known. In addition, in following stage the patient was admitted to an emergency department because of anaphylaxis. She was treated with epinephrine, corticosteroids, and inhaled beta-2 agonists. Self-injectable epinephrine was prescribed and high dose of H1-antihistamines was sustained. The relapse of hives and pruritus despite regular treatment was quite frequent. Therefore, the physicians elected to change her management and administered omalizumab subcutaneously 300 mg every 4 weeks. Within few weeks her hives ceased to occur.
No longer waiting time for promising new approaches?
In refractory patients who have failed traditional first-/second-line therapies, consideration of omalizumab, and future anti-IgE antibody biologic drugs, may represent effective options. A recent study did show long-term efficacy for omalizumab in adult patients with CU. 4 Altogether, the results of childhood case series are encouraging. 5 However, randomized controlled trials are necessary to identify both effective treatment schedule(s) and dosing for eligible patients suffering from various forms of CU unresponsive to conventional treatment. Safety profiles of omalizumab have been well described in the literature, based on use in patients with severe allergic asthma. 6 In a study population with CU, 1 patient discontinued omalizumab because of severe headache. Aside from this event, no others adverse reactions were noted in the 19 study subjects. 7 The authors have demonstrated that omalizumab was effective in the children in this series with CU. However, future studies using a standard protocol and long-term treatment inclusive of multiple CU phenotypes will be required to determine whether long lasting remission can occur and to identify the optimal dosage and duration to achieve it. Improving our understanding of the activity of omalizumab in the inflammatory process associated with various forms of CU: CIS/CSU/SU could also help to inform the decision regarding optimization of omalizumab therapy.
Conclusions
CU still poses problems with respect to reduced quality of life, lack of efficacy, and expense of current treatments for severe intractable symptoms. This case report provides evidence that the approach with fully humanized recombinant anti-IgE antibody is both feasible and acceptable in a clinical setting and therapeutically powerful for well-selected patients. Other interesting, preliminary data are the usage of omalizumab for prevention and therapy in subjects with CSU and concomitant idiopathic anaphylaxis. This is not a matter because omalizumab represents the latest development in the treatment of chronic uncontrolled urticaria. Therefore, omalizumab offers new possibilities to patients with chronic severe symptoms. School-aged children and teenagers with chronic forms of urticaria could be an appropriate target for this therapy.
Footnotes
Author Disclosure Statement
No competing financial interests exist.